false
OasisLMS
Catalog
SCCM Resource Library
Vancomycin and Piperacillin-Tazobactam or Cefepime ...
Vancomycin and Piperacillin-Tazobactam or Cefepime and Sepsis-Associated AKI Trajectory
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The research discussed in this video focuses on the use of vancomycin and piperacillin-tazobactam (VAN-TZP) or vancomycin and CEPAPIM (VAN-FEP) in patients with sepsis-associated acute kidney injury (AKI). The study found no difference in kidney-related or clinical outcomes between the two regimens in patients with pre-existing AKI. This has potential implications for the risk-benefit discussion regarding antimicrobial selection in sepsis treatment. VAN-FEP, while an alternative, carries the risk of cefepime-induced neurotoxicity, and VAN-TZP requires the addition of metronidazole. The study suggests that the use of VAN-TZP in this patient population is safe and further research is needed to explore the use of kidney biomarkers in assessing AKI and the potential mechanisms of VAN-TZP-induced nephrotoxicity.
Asset Subtitle
Pharmacology, Sepsis, Renal, 2023
Asset Caption
Type: star research | Star Research Presentations: Pharmacology II (SessionID 30016)
Meta Tag
Content Type
Presentation
Knowledge Area
Pharmacology
Knowledge Area
Sepsis
Knowledge Area
Renal
Membership Level
Professional
Membership Level
Select
Tag
Antibiotics
Tag
Sepsis
Tag
Acute Kidney Injury AKI
Year
2023
Keywords
vancomycin
piperacillin-tazobactam
CEPAPIM
sepsis-associated acute kidney injury
antimicrobial selection
×
Please select your language
1
English